Miami, FL (PRWEB) February 11, 2014 Global Stem Cells Group, Bioheart, Inc., and Paul Perito Urology announce plans to launch stem cell clinical trials for treatment of Erectile Dysfunction (ED). Paul Perito, M.D. of Perito Urology in Coral Gables, Florida and the principal investigator of the trial study, titled, "An Open-label, Non-randomized, Single-center Study to Assess the Safety and Effects of Autologous Adipose-derived Stromal Cells Delivered into the Corpus Cavernosum in Patients with Erectile Dysfunction," aims to assess the safety and efficacy of stem cell implantation therapy in patients with ED. The cell therapy in this study will be composed of stem cells derived from a patients own adipose (fat) tissue, harvested by syringe liposuction. The adipose stem cells will then be delivered into the corpus cavernosum of the penis. Clinical trials will be held at Perito Urology, in cooperation with Global Stem Cells Group and Bioheart. Up to 20 patients will be enrolled. Fort Myers Florida-based Emcyte Corporation, a leading provider of biotechnology products for platelet rich plasma and bone marrow concentrate grafting procedures, will be providing systems and kits to be used in the trial. To learn more about Global Stem Cells Group's clinical trials, and for investor … Continue reading →

(PRWEB) February 11, 2014 The report Autologous Cell Therapy (ACT) Market (2012 - 2017), would be the first global and exclusive report on ACT market. It also gives clear information about the complete industry, approved products and potential market size; it also identifies driving and restraining factors for the global ACT market with analysis of trends, opportunities and challenges. The market is segmented and revenue is forecasted on the basis of major regions such as USA, Europe and Rest of the World (ROW). Further, market is segmented and revenues are forecasted on the basis of potential application areas of ACT. Browse ACT market research data tables/figures spread through 111 slides and in-depth TOC on Autologous Cell Therapy Market". http://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html Early buyers will receive 10% customization on this report @ http://www.marketsandmarkets.com/requestCustomization.asp?id=837. The global market for ACT is valued around $650 million by 2011 with a CAGR of 21%. Several products and technologies of ACT are in pipeline which is expected to hit the market during the forecast period, which will result in increased growth rate. There is a wide market potential and favorable landscape for adoption across many geographical locations of the world. During the forecast period, these technologies are expected … Continue reading →

By Cyndi Root Friedreich's Ataxia Research Alliance (FARA) has announced in a press release that the FDA has granted orphan drug status to Edison Pharmaceuticals EPI-743 (vatiquinone). The drug treats Friedreichs ataxia, a rare nervous system disorder. Guy Miller, MD, PhD, Chairman & CEO, Edison Pharmaceuticals said, The FDAs granting of orphan designation underscores the promise that EPI-743 has for the treatment of Friedreichs ataxia. Three sites in the Friedreich's Ataxia Research Alliance (FARA) Collaborative Clinical Research Network are conducting clinical trials with EPI-743. Orphan Drug Designation Orphan drug status confers incentives to drug companies working on pharmaceutical interventions for rare diseases and conditions. The Orphan Drug Act of 1983 established the Orphan Drug Designation. The FDA grants this special designation to drugs for rare conditions that demonstrate safety and efficacy. Incentives for companies include extended market exclusivity, development cost assistance, waiver of some fees, and review of applications within six months. Friedreichs Ataxia Friedreichs ataxia is a neuro-muscular disorder. It affects adults and children with loss of coordination, vision, speech, and hearing deficits, scoliosis, diabetes, and heart problems. The disease usually degenerates until the patient is using a wheelchair and it shortens the life span. No FDA approved treatments … Continue reading →

New research is adding to a growing body of evidence showing the effects that genetics, cholesterol and other lipids in the blood have on coronary heart disease (CHD). Previous research has shown elevated levels of low-density lipoprotein cholesterol (LDLc, commonly known as bad cholesterol) are known to cause heart disease, but the effects of other lipids such as high-density lipoprotein cholesterol (HDLc, or good cholesterol) and triglycerides (TG) have been less clear. In a new study, published online in the European Heart Journal, an international team led by researchers at the Perelman School of Medicine at the University of Pennsylvania and the Childrens Hospital of Philadelphia, used a novel genetics approach integrated with cardiovascular outcomes and lipid data taken fromblood samples from study participants to target specific lipids in the blood. The approach allowed the team to rule out other behavioral or environmental factors that may contribute to heart disease. The results are lending support to existing evidence showing that levels of TG are likely associated with risk of heart disease, while elevated levels of HDLc alone do not provide protection against CHD. These results contribute to our current understanding of which blood lipids cause heart disease and which ones … Continue reading →

Contact Information Available for logged-in reporters only Newswise A comprehensive genetic analysis of invasive bladder cancer tumors has found that the disease shares genetic similarities with two forms of breast cancer, according to researchers at the University of North Carolina Lineberger Cancer Center. Bladder cancer, which is the fourth most common malignancy in men and ninth most common in women in the United States, claimed more than 15,000 patients last year. The analysis of 262 bladder cancer tumors, published online by the Proceedings of the National Academy of Sciences, reveals that the invasive form of the disease can be classified into two distinct genetic subtypes basal-like and luminal which were shown to be highly similar to the basal and luminal subtypes of breast cancer first described by Charles Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology at UNC Lineberger. A greater understanding of the genetic basis of cancers such as breast cancer has led to the development of new therapies and diagnostic aids. It will be particularly interesting to see whether the bladder subtypes, like the breast subtypes, are useful in stratification for therapy, said lead author William Kim, MD, associate professor with the UNC School of Medicine. … Continue reading →

Freeport, Bahamas (PRWEB) February 11, 2014 Matt Feshbach, CEO of Okyanos Heart Institute whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, announces the company will host a hard hat reception for conference attendees at their new facility in Freeport. The conference, titled Bridging the Gap: Research to Point of Care, brings together medical scientists, clinicians, regulatory experts, and investors to discuss progress in the field of research and clinical protocols and the process of taking promising therapies to fight chronic disease to market in a responsible manner. Gold Sponsor Okyanos Heart Institute hosts a networking reception for conference attendees at their facility in Freeport on Friday, February 21st from 5:00 7:00 p.m. The company is calling the reception a hard hat reception metaphorically as the construction is not yet completed. Chief Medical Officer Howard Walpole, M.D., M.B.A., F.A.C.C., F.S.C.A.I. and Chief Science Officer Leslie Miller, M.D., F.A.C.C. will host the reception, along with CEO Matthew Feshbach and offer tours of the commercial cath lab which will offer stem cell therapy to qualified patients with advanced coronary artery disease under the new … Continue reading →